I have always wondered why other companies haven't tried to market it to date to phase 3.
There is a report dating back to 2005 Effects of pentosan polysulfate in osteoarthritis of the knee from Perth
It was a success back then so why did no one jump on it back then.
I realize that trials cost heaps of money and take time.
Another study back in 2010 Sodium pentosan polysulfate resulted in cartilage improvement in knee osteoarthritis - An open clinical trial was a success from Japan I think so lots of info out there.
So my question is why did Paradigm jump on it and no one else?. As far as I know, Bene provides the injectable solution from their formula. Did paradigm change anything in the chemistry? Thanks for your insight Mozzarc.
PAR General discussion, page-3
-
- There are more pages in this discussion • 337 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $78.73M | |||
| Open | High | Low | Value | Volume |
| 22.5¢ | 23.0¢ | 22.0¢ | $50.00K | 222.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 172390 | 22.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 22.5¢ | 27749 | 7 |
View Market Depth
| Last trade - 13.04pm 05/11/2024 (20 minute delay) ? |
| PAR (ASX) Chart |